Doctors, Data & Decisions
Tuesday, October 6 , 2015
Stateside Theater, 719 Congress Ave.
5:15 p.m. – Doors and Bar Open
6:00 p.m. – Presentation, Q&A
7:00 p.m. – Reception
Free and open to the public
Tremendous increases in the generation and collection of medical & health data and information present opportunities to revolutionize healthcare—if this data can be accurately and rapidly analyzed. The volume of new medical reports, articles, papers, not to mention the flood of telemetry data from wearable devices, threatens to overwhelm medical practice. Persistent advances in computing capabilities that power new computational techniques including ‘deep learning’ and ‘cognitive computing’ are now enabling doctors and healthcare professionals to unlock this potential. Come learn and discuss the current state and future expectations of how computing capabilities are enabling doctors and caregivers to make more insightful, evidence-based care decisions, and thus saving, improving, and extending lives.
Rob High is an IBM Fellow, Vice President and Chief Technology Officer, Watson Solutions, IBM Software Group. He has overall responsibility to drive Watson Solutions technical strategy and thought leadership. As a key member of the Watson Solutions Leadership team, Rob works collaboratively with the Watson engineering, research, and development teams across IBM.
Prior to joining the Watson Solutions team, Rob was Chief Architect for the SOA Foundation and member of the IBM Academy of Technology, Rob championed an open industry architectural definition of the principles of business and IT alignment enabled by SOA and Business Process Optimization, as well as ensuring IBM’s software and services portfolio is architecturally grounded to enable for efficient SOA-based solutions. This responsibility extended across the IBM software portfolio, including WebSphere, Rational, Tivoli, Lotus, and Information Management offerings.
Rob has 37 years of programming experience and has worked with distributed, object oriented, component-based transaction monitors for the last 26 years, including SOMObject Server, Component Broker, and the WebSphere Application Server. Rob previously served as Chief Architect for the WebSphere foundation with architectural responsibility for the WebSphere Application Server and the related products integrated on that core runtime.
More on Rob High
Dr. Lynda Chin graduated with an M.D. degree from Albert Einstein College of Medicine in 1993 and is a board-certified dermatologist. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine, where she completed in parallel her residency training in the hospital and postdoctoral fellowship in the laboratory. She began her independent career as a private practice dermatologist in New York City, until she joined the Dana-Farber Cancer Institute and Harvard Medical School as an assistant professor in 1998, and rose to the rank of professor in 2009. Dr. Chin was also a senior associate member of the Broad Institute of MIT and Harvard. In 2011, Dr. Chin was recruited to The University of Texas MD Anderson Cancer Center to become the founding Chair of the Department of Genomic Medicine, with a mission to integrate genomics in the practice of medicine, and to bring to bear the power of big data on the cancer problem. She also serves as the Scientific Director of the Institute of Applied Cancer Science, an organization designed to bring together the best attributes of academia and industry in a new construct to rapidly translate cancer genomics knowledge into effective therapeutic endpoints.
During her 15 plus years of research career, Dr. Chin ran an impactful program spanning the fields of transcription, telomere biology, mouse models of human cancer, cancer genomics, and personalized cancer medicine. Dr. Chin has held leadership roles in The Cancer Genome Atlas (TCGA) since its pilot phase, including serving on its executive subcommittee. She conceived and led the establishment of the Disease Working Group, a structure through which disease experts outside of TCGA can interact with genomic and computational scientists in TCGA. She co-led the first marker publication from TCGA (on glioblastoma) and chaired the disease working groups for both GBM and melanoma. Internationally, Dr. Chin has been active in the formation of the International Cancer Genome Consortium, serving as leader of the working group that drafted the policy on “Clinical and Pathological Issues” and is a member of the Scientific Steering Committee. Dr. Chin’s productivity and impact as an academic researcher are reflected by her election as a member of the National Academy of Medicine (NAM – IOM) in 2012, and to the Association of American Physicians (AAP) in 2015.
Throughout her career, Dr. Chin has championed a model of integration, collaboration and cooperation between the research and clinical care enterprises, and between academia and industry. At MD Anderson, Dr. Chin has been the driver of its visionary Network Democratization Project, a cancer care transformation effort to bring MD Anderson expertise to patients everywhere. To enable this patient-centric cancer care delivery model, Dr. Chin has built a Technology Core with strategic partnership with major industry giants, including IBM-Watson to build MD Anderson Oncology Expert AdvisorTM cognitive decision support system, PwC to build a Healthcare Information Interchange to facilitate data fluidity and continuity so collaboration and coordination along the entire care delivery continuum is possible, and AT&T to develop a healthcare communication service that provides secure and compliant data and communication in motion and at rest as a foundation for a personal connected health platform that afford patients anywhere-access to the healthcare system.
Building on her work at MD Anderson, in 2015, Dr. Chin took on the Chief Innovation Officer and Associate Vice Chancellor role at the University of Texas System to build an Institute for Health Transformation, with a mission to leverage, develop and deploy innovative, technology-enabled solutions to improve access and affordability of quality healthcare in Texas and beyond. In her new role, Dr. Chin has developed a programmatic initiative to create a public-private ecosystem of technology, service, retail and healthcare industries to tackle the challenge of diabetes care and management in South Texas, for an underserved population with major unmet medical needs and significant socioeconomic barriers.
More on Lynda Chin